pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
Tolebrutinib
Phase 3 · small molecule · Non-relapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib for Non-relapsing Secondary Progressive Multiple Sclerosis is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code EFC16645
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non-relapsing Secondary Progressive Multiple Sclerosis
- Status
- completed
- Trials
- 1